Saptalis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAPTALIS PHARMS
SAPTALIS PHARMS has nine approved drugs.
There are two US patents protecting SAPTALIS PHARMS drugs.
There are five patent family members on SAPTALIS PHARMS drugs in five countries and seventy-three supplementary protection certificates in sixteen countries.
Summary for Saptalis Pharms
| International Patents: | 5 |
| US Patents: | 2 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 9 |
Drugs and US Patents for Saptalis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | 11,541,035 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Saptalis Pharms | METFORMIN HYDROCHLORIDE | metformin hydrochloride | SOLUTION;ORAL | 211309-001 | Mar 3, 2020 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Saptalis Pharms | SONAZINE | chlorpromazine hydrochloride | CONCENTRATE;ORAL | 080983-004 | Approved Prior to Jan 1, 1982 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Saptalis Pharms | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | hydrocortisone; neomycin sulfate; polymyxin b sulfate | SOLUTION/DROPS;OTIC | 065216-001 | Oct 31, 2005 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Saptalis Pharms | HYDROXYZINE HYDROCHLORIDE | hydroxyzine hydrochloride | SYRUP;ORAL | 220271-001 | Jun 11, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Saptalis Pharms | CYCLOSPORINE | cyclosporine | EMULSION;OPHTHALMIC | 211943-001 | Jul 5, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Saptalis Pharms | VOSOL HC | acetic acid, glacial; hydrocortisone | SOLUTION/DROPS;OTIC | 012770-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Saptalis Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Start Trial |
| Brazil | 112020014376 | ⤷ Start Trial |
| European Patent Office | 3768321 | ⤷ Start Trial |
| Mexico | 2020007494 | ⤷ Start Trial |
| Canada | 3087789 | ⤷ Start Trial |
| Canada | 3087789 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Saptalis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1532149 | 92128 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE |
| 2498758 | PA2020003 | Lithuania | ⤷ Start Trial | PRODUCT NAME: METFORMINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111 |
| 1506211 | PA2014026 | Lithuania | ⤷ Start Trial | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| 1666481 | LUC00031 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE SEL DE CITRATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1178 20170324 |
| 1666481 | 300887 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER TOFACITINIBCITRAAT; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| 1532149 | C300569 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720 |
| 1412357 | SPC/GB08/040 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
